Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer

Jessica J. Tao, Pau Castel, Nina Radosevic-Robin, Moshe Elkabets, Neil Auricchio, Nicola Aceto, Gregory Weitsman, Paul Barber, Borivoj Vojnovic, Haley Ellis, Natasha Morse, Nerissa Therese Viola-Villegas, Ana Bosch Campos, Dejan Juric, Saswati Hazra, Sharat Singh, Phillip Kim, Anna Bergamaschi, Shyamala Maheswaran, Tony NgFrédérique Penault-Llorca, Jason S. Lewis, Lisa A. Carey, Charles M. Perou, José Baselga, Maurizio Scaltriti

Molecular therapeutics in breast cancer

Massachusetts General Hospital
Memorial Sloan-Kettering Cancer Center
University of Auvergne
King's College London
Prometheus Therapeutics and Diagnostics
University of Illinois at Urbana-Champaign
Royal Free Hospital
University of North Carolina

Research output: Contribution to journal › Article › peer-review

Sort by
Weight
Alphabetically

Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer

Fingerprint

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry

Neuroscience

Biochemistry, Genetics and Molecular Biology